Evotec and Research Support International Form Joint Venture Evotec-RSIL Ltd
News Jul 11, 2007
Evotec AG and Research Support International Limited (RSIL), a subsidiary of DIL Ltd, have announced the formation of a joint venture in India, Evotec-RSIL Ltd, to design, synthesise and manage compound libraries as a service.
The joint venture will combine Evotec’s expertise in library design, synthesis, analysis, purification and project management with RSIL’s first class scientists coupled with a low cost structure in India to provide a high quality, cost efficient solution for the provision and management of compound libraries to the pharmaceutical industry.
The joint venture will be located in Thane, India, and will use newly constructed laboratories. Evotec will contribute its proprietary technologies, years of experience and expertise in library synthesis in addition to providing a range of parallel synthesis equipment, high throughput analytical apparatus and expert training in the design, synthesis and management of compound libraries.
Evotec-RSIL Ltd will design compound libraries of low hundreds to thousands of compounds per scaffold by accessing chemistries already validated at Evotec and/or RSIL. As well as being able to design and synthesise compound libraries the joint venture will also offer library management services in which it will be able to analyse and purify large screening libraries in a cost efficient manner.
“Evotec has enjoyed an enviable reputation in the synthesis of large screening and focused libraries for many years. Through this joint venture we are able to team up with the excellent scientists and management at RSIL to continue to provide this invaluable service at competitive prices for our customers. We are very pleased to collaborate with RSIL, one of India’s premier chemistry services business“, commented Dr Mario Polywka, Chief Operating Officer of Evotec.
“With the formation of this joint venture through a contribution in kind of Evotec’s library business, Evotec is making another significant step in its strategy to focus its core business in Europe on high value solutions and products for the pharmaceutical industry,” Polywka continued.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE